NCT02029573已完成2 期
Phase II Study of Atorvastatin in Combination With Radiotherapy and Temozolomide in Glioblastoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 36
- 试验地点
- 1
- 主要终点
- Progression free survival at 6 months (PFS-6)
研究概览
简要总结
The purpose of this study is to explore the efficacy and safety of Atorvastatin in combination with multimodality therapy of concurrent radiotherapy plus temozolomide followed by adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme (GBM).The anticipated time on study treatment is until disease progression, and the target sample size is 32 individuals.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically proven newly diagnosed Malignant Glioblastoma Multiforme or variants (gliosarcoma, glioblastoma with oligodendroglial features, giant cell glioblastoma).
- •Age ≥ 18 years.
- •Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or
- •Patients must have an estimated life expectancy of at least 12 weeks.
- •No prior chemotherapy or radiotherapy.
- •Stable dose of steroid for ≥ 14 days prior to registration.
- •Patients must have adequate bone marrow function (e.g., hemoglobin ≥10 g/dl, absolute granulocyte count ≥ 1.5 x 109/L, and platelet count ≥100 x 109/L.
- •Adequate liver function (SGPT, SGOT, and alkaline phosphatase ≤ 2.5 times upper limits of normals (ULN) and total bilirubin ≤1.5 x ULN), and adequate renal function (BUN or creatinine ≤1.5 X ULN) prior to starting therapy.
- •Paraffin embedded tumour sample available for study.
- •Patient consent must be obtained according to local Institutional requirements. The patient must sign the consent form prior to registration.
- •Protocol treatment is to begin within 10 working days of patient registration.
排除标准
- •Pregnant or lactating women; men and women of childbearing potential must agree to practice an effective method of birth control. Women of childbearing potential must have a negative pregnancy test performed within 14 days prior to registration.
- •Concurrent treatment with other experimental drugs or anticancer therapy.
- •Patients with a history of other malignancies, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours curatively treated with no evidence of disease for > 5 years.
- •Prior radiotherapy or systemic cytotoxic chemotherapy .
- •Severe, active co-morbidity, defined as follows: Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration, Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or oxygen, Hepatic insufficiency or Active liver disease resulting in clinical jaundice and/or coagulation defects, Acquired immune deficiency syndrome (AIDS) , Significant neurologic or psychiatric disorder which would impair the ability to obtain informed consent, Active uncontrolled or serious infection, active peptic ulcer disease, Any medical condition which could interfere with oral medication intake (e.g., frequent vomiting, partial bowel obstruction), Myocardial infarction within 6 months prior to registration, Congestive heart failure, unstable angina, active cardiomyopathy, cardiac arrhythmia, Skeletal muscle disease and other related reticule-endothelial diseases.
- •Patients with known hypersensitivity to the study drugs or their components.
研究组 & 干预措施
Atorvastatin in Combination With Radiotherapy and Temozolomide
Experimental
干预措施: Atorvastatin (Drug)
Atorvastatin in Combination With Radiotherapy and Temozolomide
Experimental
干预措施: Temozolomide (Drug)
Atorvastatin in Combination With Radiotherapy and Temozolomide
Experimental
干预措施: Radiotherapy (Radiation)
结局指标
主要结局
Progression free survival at 6 months (PFS-6)
时间窗: up to 6 months
All efficacy determinations will be based on the Response Assessment in Neuro-Oncology (RANO) response criteria (Wen 2010)
次要结局
- Progression free survival(Up to 2-3 years)
- Overall Survival (OS)(Up to 2-3 years)
- Adverse events(Up to 2-3 years)
研究者
Abdullah Khalaf Altwairgi
Medical Oncologist
King Fahad Medical City
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Atorvastatin in New Onset Type 1 Diabetes Mellitus (T1DM)Type 1 DiabetesNCT00529191Children's Hospital of Philadelphia40
撤回
不适用
The Pleiotropic Effects of Atorvastatin When Combined With Common Antihypertenisve Medications.HypertensionNCT00656331University of New Mexico
终止
1 期
Dose Escalation Phase I/II Study of Lovastatin With High-Dose Cytarabine for Refractory or Relapsed AMLAcute Myeloid LeukemiaNCT00583102University of Iowa23
Unknown
2 期
The Clinical Study of Atorvastatin and Dexamethasone on Treatment for Chronic Subdural Hematoma in the Patients With Coagulation DisordersChronic Subdural HematomaNCT02192320Oriental Neurosurgery Evidence-Based-Study Team60
已完成
4 期
Additive Beneficial Effects of Atorvastatin Combined With Amlodipine In Treatment of HypertensionHypertensionNCT00741078Gachon University Gil Medical Center